2-[4-(Prop-2-enamido)phenyl]acetic acid | 41948-63-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[4-(Prop-2-enamido)phenyl]acetic acid
• 英文别名: 2-[4-(prop-2-enoylamino)phenyl]acetic acid
• CAS: 41948-63-4
• 化学式: C₁₁H₁₁NO₃
• 分子量: 205.21
• InChiKey: IVFRPHRPKVUJDZ-UHFFFAOYSA-N

物化性质

• 沸点：
  448.2±37.0 °C(Predicted)
• 密度：
  1.270±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Engineered antibody fragment that irreversibly binds an antigen
  申请人：Meares F. Claude

  公开号：US20060063209A1

  公开（公告）日：2006-03-23

  The present invention provides mutant antibodies with infinite affinity for a target antigen. The antibodies comprise a mutant amino acid at a position within or proximate to a complimentarity determining region of the antibody and a linker covalently bound to the mutant amino acid, the linker comprising a reactive functional group. Subsequent to binding an antigen, the reactive functional group is converted to a covalent bond by reaction with a group of complementary reactivity on the bound antigen. The invention also provides bispecific antibodies with infinite binding affinity that comprise a second domain that specifically binds a metal chelate. The invention further provides methods of using such antibodies to diagnose and treat diseases and conditions.

  本发明提供了对目标抗原具有无限亲和力的突变抗体。这种抗体包括位于抗体互补决定区内或附近位置的突变氨基酸，以及与突变氨基酸共价结合的连接体，连接体包括反应性官能团。在结合抗原后，活性官能团通过与结合抗原上的互补反应基团反应转化为共价键。本发明还提供了具有无限结合亲和力的双特异性抗体，该抗体包含第二个结构域，可特异性结合金属螯合物。本发明进一步提供了使用这种抗体诊断和治疗疾病和病症的方法。
• ENGINEERED ANTIBODY FRAGMENT THAT IRREVERSIBLY BINDS AN ANTIGEN
  申请人：The Regents of the University of California

  公开号：EP1789087A2

  公开（公告）日：2007-05-30
• [EN] ENGINEERED ANTIBODY FRAGMENT THAT IRREVERSIBLY BINDS AN ANTIGEN<br/>[FR] FRAGMENT D'ANTICORPS GENETIQUEMENT MODIFIE QUI SE LIE A UN ANTIGENE DE MANIERE IRREVERSIBLE
  申请人：UNIV CALIFORNIA

  公开号：WO2006033742A2

  公开（公告）日：2006-03-30

  The present invention provides mutant antibodies with infinite affinity for a target antigen. The antibodies comprise a mutant amino acid at a position within or proximate to a complimentarity determining region of the antibody and a linker covalently bound to the mutant amino acid, the linker comprising a reactive functional group. Subsequent to binding an antigen, the reactive functional group is converted to a covalent bond by reaction with a group of complementary reactivity on the bound antigen. The invention also provides bispecific antibodies with infinite binding affinity that comprise a second domain that specifically binds a metal chelate. The invention further provides methods of using such antibodies to diagnose and treat diseases and conditions.
• [EN] METHODS FOR DETERMINING PRESENCE OF VASCULAR PLAQUES USING PRETARGETING REAGENT AND AB-SN CONJUGATES<br/>[FR] PROCÉDÉ PERMETTANT DE DÉTERMINER LA PRÉSENCE DE PLAQUES VASCULAIRES AU MOYEN D'UN RÉACTIF DE PRÉCIBLAGE ET DE CONJUGUÉS AB-SN
  申请人：UNIV CALIFORNIA

  公开号：WO2009070787A1

  公开（公告）日：2009-06-04

  This invention encompasses a protein that has the property of irreversible capture of the element tin, chelated within a special analog of the hapten DOTA. The invention is the 2D12.5 Fab, G54C mutant previously described. The invention is based on the previously unstudied properties of Tin-DOTA, which shows high stability under physiological conditions, and surprising affinity of the 2D12.5 Fab, G54C mutant for a tin- DOTA complex.